ProMIS Neurosciences

ProMIS Neurosciences FCF/Debt

The Free Cash Flow to Debt Ratio of ProMIS Neurosciences (PMN) as of Nov 8, 2026 is -238.36 %. In the previous year, Free Cash Flow to Debt Ratio was -2,133.33 % — a change of -88.83% (higher).

FCF/Debt

-238.36 %

YoY

-88.83%

Last updated:

Free Cash Flow to Debt Ratio of ProMIS Neurosciences is 2021 -238.36 % . Free Cash Flow to Debt Ratio of ProMIS Neurosciences was 2020 -2,133.33 % . It decreases by -88.83% higher compared to the previous year.

The ProMIS Neurosciences FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2015
-1,366.67 USD
Jan 1, 2016
-2,133.33 USD
Jan 1, 2021
-238.36 USD
The ProMIS Neurosciences FCF/Debt history
YEARFCF/DebtYoY
-238.36 %-88.83%
-2,133.33 %+56.10%
-1,366.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProMIS Neurosciences Stock analysis

What does ProMIS Neurosciences do? ProMIS Neurosciences develops precision medicine solutions targeting neurodegenerative diseases like Alzheimer’s, ALS, and MSA through proprietary antibody therapeutics. Its product portfolio includes PMN310 for amyloid-beta, PMN267 for TDP-43, and PMN442 for alpha-synuclein, leveraging its ProMIS and Collective Coordinates platforms to identify Disease Specific Epitopes on misfolded proteins. The company focuses on early detection and treatment, with plans to expand into Parkinson's and dementia with Lewy bodies. Its wholly owned subsidiary, ProMIS Neuro, supports these therapeutic development efforts. The firm generates revenue through the development and potential commercialization of its antibody therapeutics, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for neurodegenerative conditions. Its focus on misfolded proteins in diseases like AD, ALS, and MSA positions it to address unmet medical needs in specialized therapeutic segments. The company’s approach combines computational discovery with antibody development to create targeted solutions for complex neurological disorders. ProMIS Neurosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProMIS Neurosciences stock

Free Cash Flow to Debt Ratio of ProMIS Neurosciences is -238.36 % in 2021.

Free Cash Flow to Debt Ratio of ProMIS Neurosciences changed from -2,133.33 % to -238.36 %, representing a -88.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio ProMIS Neurosciences since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's ProMIS Neurosciences with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ProMIS Neurosciences

All Key Metrics — ProMIS Neurosciences